TCT-473 Efficacy and safety of abciximab administration in contemporary primary percutaneous coronary intervention  by García-Tejada, Julio et al.
Table. Thirty-Day and One-Year Outcomes
Thirty-Day
Outcomes
Excess Dose
(N¼543)
Recommended
Dose (N¼4,744) HR [95%CI] p-Value
All-cause death 17 (3.1) 56 (1.2) 2.70
[1.59, 4.76]
0.0002
Reinfarction 39 (7.3) 301 (6.4) 1.15
[0.83, 1.61]
0.41
Stent thrombosis
(def/prob)
16 (3.0) 79 (1.7) 1.82
[1.06, 3.13]
0.03
Non-CABG major
bleeding
69 (12.8) 329 (7.0) 1.89
[1.47, 2.44]
<0.0001
MACE 57 (10.5) 399 (8.5) 1.27
[0.96, 1.69]
0.09
NACE 106 (19.6) 650 (13.8) 1.49
[1.20, 1.82]
<0.0001
One-Year Outcomes
All-cause death 40 (7.5) 148 (3.7) 2.44
[1.72, 3.45]
<0.0001
Reinfarction 62 (11.8) 415 (9.1) 1.33
[1.03, 1.75]
0.03
Stent thrombosis
(def/prob)
18 (3.4) 113 (2.6) 1.45
[0.88, 2.38]
0.15
MACE 114 (21.3) 772 (17.3) 1.33
[1.10, 1.61]
0.004
Values presented as n (%). MACE¼Major Adverse Cardiovascular Events (death, myocardial
infarction unplanned revascularization for ischemia, stroke); NACE¼Net Adverse Clinical
Events (MACE or major bleeding).
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMTCT-473
Efﬁcacy and safety of abciximab administration in contemporary primary
percutaneous coronary intervention
Julio García-Tejada1, Jurado-Roman Alfonso1, Carolina Granda1,
Agustin Albarran1, Felipe Henandez1, M. Teresa Velazquez1,
Roberto Martin-Asenjo1, Belen Rubio1, Sandra Mayordomo1, Juan C. Tascon1
1University Hospital 12 de Octubre, Madrid, Spain
Background: With the widespread use of high loading dose of clopidogrel or new
P2Y12 receptor inhibitors, limited data are available regarding the efﬁcacy and safety
of the administration of a glycoprotein IIb/IIIa inhibitor to patients with ST-segment
elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary
intervention (PPCI). Thus, we analyzed the short-term results of abciximab admin-
istration to a contemporary cohort of STEMI patients undergoing PPCI.
Methods: Between July-2012 and April-2014, 482 STEMI patients underwent PPCI
in a tertiary care hospital. All patients were preloaded with aspirin and a thienopir-
idine. 94% of the patients were treated with unfractioned heparin and 6% with
bivalirudin. PPCI was performed via transradial approach in 84% of cases. We
compared the clinical characteristics and the 30-day outcome between 2 groups of
patients: those treated with abciximab (group A, n¼287) and those treated without
(group B, n¼195).
Results: Patients in group A were younger, more frequently men, had more body
weight, hypertension, multivessel disease and thrombus burden than patients in group
B. Preloading with clopidogrel (group A: 78% vs group B: 73%, p¼0.2) and/or with a
new P2Y12 receptor inhibitor (group A: 30% vs. group B: 38%, p¼0.1) was similar in
both groups. At 30 days, the efﬁcacy endpoint (composite of death, reinfarction, new
target-vessel revascularization or ischemic stroke) was observed less frequently in
group A than in group B (5.5% vs. 11.7%, respectively, p¼0.02), while the safety
endpoint (BARC type 3 bleeding) occurred similarly in both groups of patients
(group A: 4.1% vs. group B: 3.5%, p¼0.7). The net adverse clinical event rate
(combination of the efﬁcacy and safety endpoints) was also similar in both groups of
patients (group A: 9.7%vs. group B: 15.3%, p¼0.06).
Conclusions: In contemporary PPCI, administration of abciximab to selected patients
appears safe and effective, and is potentially associated with a reduction in adverse
ischemic event rate, without an increase in major bleeding risk.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/PhaPharmacotherapy - Chronic anticoagulants
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Acute Coronary Syndromes: The AVIATOR Registry
Georgios Christodoulidis1, Marco G. Mennuni2, Samantha Sartori3, usman baber4,
George Dangas5, Samin Sharma6, Annapoorna Kini7, Corrado Tamburino8,
Alaide Chieffo9, Antonio Colombo10, Patrizia Presbitero11, Roxana Mehran12
1Mount Sinai Medical Center, New York, NY, 2Istituto Clinico Humanitas, Rozzano,
Milan, Italy, 3Mount Sinai School of Medicine, New York, NY, 4Mount Sinai, New
York, NY, 5Mount Sinai, New York, New York, NY, 6Mount Sinai School of Medicine,
New York, United States, 7mount sinai, New York, United States, 8University of
Catania, Catania, Italy, 9San Raffael Scientiﬁc Institute, Milan, Italy, Milan, Italy,
10EMO GVM Centro Cuore Columbus/San Raffaele Hospital, Milan, Italy,
11Humanitas Institute, Milan, ID, 12Mount Sinai Hospital, New York, United States
Background: Current guidelines recommend dual antiplatelet therapy (DAPT) in
patients with acute coronary syndrome (ACS) treated with percutaneous coronary
intervention (PCI) and anticoagulation for stroke protection in patients with atrial
ﬁbrillation (AF) and CHADS2 scores 2, but optimum antithrombotic therapy in
patients with AF undergoing PCI for ACS remains controversial.
Methods: Among 859 consecutive patients with AF treated with PCI in the AVIA-
TOR (Antithrombotic strategy Variability InATrial ﬁbrillation and Obstructive coro-
nary disease Revascularized with PCI) registry, 425 presented with ACS. Patients
were stratiﬁed according to medications at discharge: triple therapy (TT; warfarin +
DAPT) or DAPT (aspirin + clopidogrel). Major adverse cardiovascular events
(MACE; death, myocardial infarction, stroke) and clinically relevant bleeding (BARC
2) were compared between groups over 1 year.
Results: Mean age was similar in the 2 groups (74  9 years). Patients receiving TT
(n¼185, 43.5%) were more often male with higher ejection fraction and more likely to
receive bare metal stents than patients discharged on DAPT (n¼240, 56.5%). The
1-year incidence of MACE was similar in the TT vs. DAPT groups (14 vs. 16%,
adjusted HR 0.9; p¼0.78) but patients on TT more often developed bleeding (13 vs.
6%, adjusted HR 2.05 p¼0.03; Figure).
Conclusions: DAPT was more often prescribed in these patients with AF and
CHADS2 scores 2 undergoing PCI for ACS. Compared to patients on DAPT, those
given TT had similar 1-year rates of MACE but more bleeding.TCT-475
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Background: Optimal antithrombotic regimen for patients with atrial ﬁbrillation (AF) un-
dergoing drug-eluting stent (DES) implantation for complex coronary artery disease is un-
certain.Theaimof study is to compare thenet clinical outcomesbetween triple antithrombotic
therapy group (TAT; aspirin, thienopyridine and warfarin) and dual antiplatelet therapy
group (DAPT; aspirin and thienopyridine) in AF patients undergoing DES implantation.
Methods: Among a total of 367 AF patients undergoing DES implantation, 154 pa-
tients (42.0%) received TAT and 213 patients (58.0%) received DAPT. The prescribedrmacotherapy - Chronic anticoagulants (warfarin and newer agents) B139
